Estado actual en el tratamiento de la enfermedad de Chagas

Efficient drugs against Chagas' disease must have an effect on the amastigote forms or intracellular reproduction elements of Trypanosoma cruzi (T. cruzi). Trypomastigote and epimastigote forms derive from the former and their response to medications is less marked. The only drugs used in human...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	APT B,WERNER, ZULANTAY A,INÉS
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Benzonidazole Chagas cardiomyopathy Chagas disease
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000200016
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011000200016
record_format	dspace
spelling	oai:scielo:S0034-988720110002000162011-08-01Estado actual en el tratamiento de la enfermedad de ChagasAPT B,WERNERZULANTAY A,INÉS Benzonidazole Chagas cardiomyopathy Chagas disease Efficient drugs against Chagas' disease must have an effect on the amastigote forms or intracellular reproduction elements of Trypanosoma cruzi (T. cruzi). Trypomastigote and epimastigote forms derive from the former and their response to medications is less marked. The only drugs used in humans are nifurtimox (NF) and benznidazole (BNZ). Other useful medications are allopurinol and itraconazole. NF acts producing free radicals and BNZ inhibits the synthesis of macromolecules. There is consensus that Chagas' disease must be treated in all its periods, since T.cruzi DNA is detected by polymerase chain reaction in chronic cases, even when microscopy is negative. The pharmacological treatment modifies the natural evolution of the disease. It also helps to solve a public health problem, considering that there is a high number of subjects with Chagas' disease. Subjects with chronic chagasic cardiomyopathy with terminal heart failure are the only cases without indication for treatment. Due to the digestive and skin secondary effects of the drugs, treated patients must be controlled clinically and with complete blood counts and hepatic proiles before, during and after the therapy. Approximately 30% of patients will experience secondary effects. Children have a better tolerance to the drugs. Congenital or acquired acute, intermediate and chronic cases should be treated.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.2 20112011-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000200016es10.4067/S0034-98872011000200016
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Benzonidazole Chagas cardiomyopathy Chagas disease
spellingShingle	Benzonidazole Chagas cardiomyopathy Chagas disease APT B,WERNER ZULANTAY A,INÉS Estado actual en el tratamiento de la enfermedad de Chagas
description	Efficient drugs against Chagas' disease must have an effect on the amastigote forms or intracellular reproduction elements of Trypanosoma cruzi (T. cruzi). Trypomastigote and epimastigote forms derive from the former and their response to medications is less marked. The only drugs used in humans are nifurtimox (NF) and benznidazole (BNZ). Other useful medications are allopurinol and itraconazole. NF acts producing free radicals and BNZ inhibits the synthesis of macromolecules. There is consensus that Chagas' disease must be treated in all its periods, since T.cruzi DNA is detected by polymerase chain reaction in chronic cases, even when microscopy is negative. The pharmacological treatment modifies the natural evolution of the disease. It also helps to solve a public health problem, considering that there is a high number of subjects with Chagas' disease. Subjects with chronic chagasic cardiomyopathy with terminal heart failure are the only cases without indication for treatment. Due to the digestive and skin secondary effects of the drugs, treated patients must be controlled clinically and with complete blood counts and hepatic proiles before, during and after the therapy. Approximately 30% of patients will experience secondary effects. Children have a better tolerance to the drugs. Congenital or acquired acute, intermediate and chronic cases should be treated.
author	APT B,WERNER ZULANTAY A,INÉS
author_facet	APT B,WERNER ZULANTAY A,INÉS
author_sort	APT B,WERNER
title	Estado actual en el tratamiento de la enfermedad de Chagas
title_short	Estado actual en el tratamiento de la enfermedad de Chagas
title_full	Estado actual en el tratamiento de la enfermedad de Chagas
title_fullStr	Estado actual en el tratamiento de la enfermedad de Chagas
title_full_unstemmed	Estado actual en el tratamiento de la enfermedad de Chagas
title_sort	estado actual en el tratamiento de la enfermedad de chagas
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000200016
work_keys_str_mv	AT aptbwerner estadoactualeneltratamientodelaenfermedaddechagas AT zulantayaines estadoactualeneltratamientodelaenfermedaddechagas
_version_	1718436554284728320

Estado actual en el tratamiento de la enfermedad de Chagas

Ejemplares similares